Skip to Main content Skip to Navigation
Journal articles

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

Abstract : Tumour-associated KRAS mutations are the most prevalent in the three RAS-family isoforms and involve many different amino-acids. Therefore, molecules able to interfere with mutant KRAS protein are potentially important for wide-ranging tumour therapy. We describe the engineering of two RAS degraders based on protein macromolecules (macrodrugs) fused to specific E3 ligases. A KRAS-specific DARPin fused to the VHL E3 ligase is compared to a pan-RAS intracellular single domain antibody (iDAb) fused to the UBOX domain of the CHIP E3 ligase. We demonstrate that while the KRAS-specific DARPin degrader induces specific proteolysis of both mutant and wild type KRAS, it only inhibits proliferation of cancer cells expressing mutant KRAS in vitro and in vivo. Pan-RAS protein degradation, however, affects proliferation irrespective of the RAS mutation. These data show that specific KRAS degradation is an important therapeutic strategy to affect tumours expressing any of the range of KRAS mutations.
Complete list of metadatas

Cited literature [62 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02907974
Contributor : Myriam Bodescot <>
Submitted on : Tuesday, July 28, 2020 - 9:52:03 AM
Last modification on : Tuesday, August 4, 2020 - 9:19:50 AM
Long-term archiving on: : Tuesday, December 1, 2020 - 8:36:56 AM

File

s41467-020-17022-w.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Nicolas Bery, Ami Miller, Terry Rabbitts. A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.3233. ⟨10.1038/s41467-020-17022-w⟩. ⟨inserm-02907974⟩

Share

Metrics

Record views

30

Files downloads

34